

## Curriculum Vitae: Mark Waer

ADDRESS: Labo Experimentele Transplantatie  
Katholieke Universiteit Leuven  
Campus Gasthuisberg  
Herestraat 49  
3000 Leuven  
Tel: + 32 16 34 60 22  
Fax : +32 16 34 60 35  
E-mail: mark.waer@med.kuleuven.be

Vicerector / Hoofd Biomedische Wetenschappen  
Katholieke Universiteit Leuven  
Campus Gasthuisberg  
Herestraat 49  
3000 Leuven  
Tel : +32 16 33 02 86  
Fax: + 32 16 33 02 12  
E-mail: mark.waer@gbiomed.kuleuven.be

CITIZENSHIP: Belgium

EDUCATION: 1976 Medical Doctor "Magna cum laude", University of Leuven (K.U.Leuven), Belgium.  
1981 Specialist internal Medicine - Nephrology, University of Leuven (K.U.Leuven), Belgium  
1983 Ph.D. Medical Sciences, Faculty of Medicine University of Leuven (K.U.Leuven), Belgium.  
"Immunological effects of fractionated total lymphoid irradiation on the induction of transplantation tolerance and in the treatment of autoimmune disorders".  
1983 -1985 Post-doctorate fellow, Medicine-Immunology, Stanford University, Stanford Ca 94305, V.S.A.

### PROFESSIONAL APPOINTMENTS:

1985 – 1992: "Adjunct Chief of Clinic" Nephrology Department, University of Leuven (K.U.Leuven), Belgium.  
1992 - Professor (tenure) Faculty of Medicine, University of Leuven (K.U.Leuven), Belgium.  
1994 - Director Laboratory for Experimental Transplantation, University of Leuven (K.U.Leuven), Belgium.  
1998 – 2005: Medical Director University Hospitals, University of Leuven (K.U.Leuven), Belgium.  
1999 – 2003: Part-time Adviser of the National Minister of Health for academic and specialized medicine matters.  
2003 – 2005: President of the Immunology Branch of the Belgian National Fund for Medical Research  
2006 – 2007: General Director ad-interim University Hospitals, University of Leuven (K.U.Leuven), Belgium.  
2005- Vice President (vice rector) Biomedical Sciences, University of Leuven (K.U.Leuven), Belgium.  
2006- Chairman of the University Hospitals, University of Leuven (K.U.Leuven), Belgium.

### HONORS:

1983: Fulbright Hays Award for Medical Research  
1983: NATO Award for Medical Research  
1984: Post-doctorate fellowship, Stanford University, U.S.A.  
1986: Award of the Belgian Immunological Society for the best presentation, International Congress of Immunology, Toronto, Canada  
1989: Award of "Levenslijn" for anticancer treatment using bone marrow transplantation  
1992: Award of "Vereniging voor Kankerbestrijding" for studies dealing with leukemia recurrence after bone marrow transplantation  
1995: Award of the European Society of Organ Transplantation for the best oral communication during the Congress in Vienna  
1996: Award of "Levenslijn" for studies dealing with Xenotransplantation for pancreas islets  
2004-2005: Belgian Francqui-chair at the University of Antwerp: Immunobiology and Immunotherapy.

#### RESEARCH INTERESTS:

##### Transplantation Immunology:

Induction of transplantation tolerance, bone marrow chimerism, new immunosuppressants, xenotransplantation

##### Tumor Immunology:

Immunological defense mechanisms against cancer, graft versus leukemia effect

##### Autoimmunity:

Immune mechanism in experimental models for multiple sclerosis, diabetic, Crohn's disease, arthritis

#### SCIENTIFIC ACTIVITIES ABROAD:

1983-1985 Post-doctorate fellowship, Dept. Medicine, Division Immunology (Dir. Prof. Dr. S. Strober), Stanford University, Stanford 94305, U.S.A.

#### PRESENT POSITIONS:

- Vice President (vice rector) Biomedical Sciences, University of Leuven (K.U.Leuven), Belgium.
- Professor of Immunology, University of Leuven (K.U.Leuven), Belgium.
- Chairman of the University Hospitals, University of Leuven (K.U.Leuven), Belgium.
- Director Laboratory of Experimental Transplantation, University of Leuven (K.U.Leuven), Belgium.
- Member of the Royal Academy Medicine of Belgium.

#### SCIENTIFIC ACTIVITIES:

- Member of the Editorial board of "Transplantation"
- Author and co-author of more than 200 publications in international peer-review - journals
- Author of several chapters in Handbooks of Nephrology (e.g. Massry and Glasscock: Textbook of Nephrology) and Transplantation (e.g. P. Morris, Kidney Transplantation; Ginns, Cosimi and Morris: Transplantation; Baumgartner, Reitz and Achuff: Heart and Heart-Lung Transplantation)
- Co-founder (2002) of "4AZA Bioscience" a spin-off bioscience company developing new 'small molecules' for immunotherapy.

#### BIBLIOGRAPHY:

1. Billiau A, Bloemmen J, Bogaerts M et al. Interferon therapy in multiple myeloma: failure of human fibroblast interferon administration to the course of light chain disease. *Eur.J.Cancer Clin.Oncol.* 1981;17:875-882.
2. **Waer M**, Ang KK, Vandeputte M, van der SE. Influence of overall treatment time in a fractionated total lymphoid irradiation as an immunosuppressive therapy in allogeneic bone marrow transplantation in mice. *Int.J.Radiat.Oncol.Biol.Phys.* 1982;8:1915-1921.
3. Ang KK, **Waer M**, van der SE, Vandeputte M. Facilitation of allogeneic bone marrow engraftment in mice by total lymphoid irradiation combined with total-body irradiation. *Transplantation.* 1983;36:11-15.
4. Vanrenterghem Y, **Waer M**, Ang KK et al. Renal cadaveric transplantation after total lymphoid irradiation in patients with diabetes. *Kidney Int.Suppl.* 1983S-73.
5. **Waer M**, Ang KK, van der SE, Vandeputte M. Increased incidence of murine graft-versus-host disease after allogeneic bone marrow transplantation by previous infusion of syngeneic bone marrow cells. *Transplantation.* 1984;38:396-400.
6. Vanrenterghem Y, Waer M, Ang K et al. Cadaveric kidney transplantation in diabetics after total lymphoid irradiation (TLI). *Transplant.Proc.* 1984;16:636-639.
7. **Waer M**, Ang KK, van der SE, Vandeputte M. Allogeneic bone marrow transplantation in mice after total lymphoid irradiation: influence of breeding conditions and strain of recipient mice. *J.Immunol.* 1984;132:991-996.
8. **Waer M**, Ang KK, van der SE, Vandeputte M. Influence of radiation field and fractionation schedule of total lymphoid irradiation (TLI) on the induction of suppressor cells and stable chimerism after bone marrow transplantation in mice. *J.Immunol.* 1984;132:985-990.
9. **Waer M**, Vanrenterghem Y, Ang KK et al. Comparison of the immunosuppressive effect of fractionated total lymphoid irradiation (TLI) vs conventional immunosuppression (CI) in renal cadaveric allotransplantation. *J.Immunol.* 1984;132:1041-1048.
10. **Waer M**, Vanrenterghem Y, Roels L et al. Total lymphoid irradiation in renal cadaveric transplantation in diabetics. *Lancet.* 1985;2:1354.
11. Levin B, Hoppe RT, Collins G et al. Treatment of cadaveric renal transplant recipients with total lymphoid irradiation, antithymocyte globulin, and low-dose prednisone. *Lancet.* 1985;2:1321-1325.

12. Ang KK, Vanrenterghem Y, **Waer M** et al. Kidney allograft tolerance in diabetic patients after total lymphoid irradiation (TLI). *Radiother.Oncol.* 1985;3:193-199.
13. Michielsen P, Van DB, Hauglustaine D et al. [Acute renal insufficiency: 1st manifestation of familial sarcoidosis]. *Nephrologie.* 1985;6:151-152.
14. Hauglustaine D, **Waer M**, Michielsen P, Goebels J, Vandeputte M. Haemodialysis membranes, serum beta 2-microglobulin, and dialysis amyloidosis. *Lancet.* 1986;1:1211-1212.
15. Wilms G, Oyen R, **Waer M**, Baert AL, Michielsen P. CT demonstration of aneurysms in polyarteritis nodosa. *J.Comput.Assist.Tomogr.* 1986;10:513-515.
16. **Waer M**, Ceuppens JL, Vanrenterghem Y et al. Identification of a major Leu 7/OKT 8 positive T-lymphocyte subpopulation in renal transplant patients pre-treated with total lymphoid irradiation. *Leuk.Res.* 1986;10:883-886.
17. Vanrenterghem Y, **Waer M**, Roels L, Lerut T, Michielsen P. Is cyclosporine-associated nephrotoxicity progressive? *Transplant.Proc.* 1987;19:4031-4032.
18. Vanrenterghem Y, Roels L, Lerut T et al. Long-term prognosis after cadaveric kidney transplantation. *Transplant.Proc.* 1987;19:3762-3764.
19. **Waer M**, Vanrenterghem Y, Roels L et al. Immunological and clinical observations in diabetic kidney graft recipients pretreated with total-lymphoid irradiation. *Transplantation.* 1987;43:371-379.
20. Vanrenterghem Y, Roels L, **Waer M** et al. Impact of HLA-DR and combined HLA-B and HLA-DR matching on early graft outcome under cyclosporine therapy. *Transplant.Proc.* 1987;19:685-686.
21. **Waer M**, Vanrenterghem Y, van der SE, Michielsen P, Vandeputte M. Identification and function of a major OKT3, OKT8, Leu-7, positive lymphocyte subpopulation in renal transplant recipients treated with total lymphoid irradiation. *Transplant.Proc.* 1987;19:1570-1571.
22. Vanrenterghem Y, **Waer M**, Roels L, Michielsen P. A controlled trial comparing pretransplant total lymphoid irradiation versus posttransplant cyclosporine in type I diabetic cadaveric kidney graft recipients: short-term results. *Transplant.Proc.* 1987;19:1542-1543.
23. **Waer M**, Van DB, Leenaerts P et al. Treatment of murine lupus nephritis with cyclophosphamide or total lymphoid irradiation. *Kidney Int.* 1988;34:678-682.
24. **Waer M**, Vanrenterghem Y, Roels L et al. Renal cadaveric transplantation in diabetics using total lymphoid irradiation or cyclosporin A. A controlled randomized study. Leuven Collaborative Transplantation Group. *Transpl.Int.* 1988;1:64-68.
25. Verresen L, **Waer M**, Verberckmoes R, Morias P, Michielsen P. Primary sclerosing cholangitis associated with membranous nephropathy. *Ann.Intern.Med.* 1988;108:909-910.
26. Vanrenterghem Y, **Waer M**, De KP, Roels L, Michielsen P. Controlled trial of the protective effect of dihydroergotoxine (Hydergine) on cyclosporine-associated nephrotoxicity in renal graft recipients. *Transplant.Proc.* 1988;20:615-617.
27. Vanrenterghem Y, **Waer M**, Roels L et al. Shortage of kidneys, a solvable problem? The Leuven experience. Leuven Collaborative Group for Transplantation. *Clin.Transpl.* 1988;91-97.
28. Verresen L, Vanrenterghem Y, **Waer M**, Hauglustaine D, Michielsen P. Corticosteroid withdrawal syndrome in dialysis patients. *Nephrol.Dial.Transplant.* 1988;3:476-477.
29. De RD, **Waer M**, Vandeputte M, van der SE. Immunologic changes after loco-regional radiotherapy and fractionated total body irradiation (TBI) in mice. *Int.J.Radiat.Oncol.Biol.Phys.* 1989;17:1237-1245.
30. Marchal G, Rigauts H, Van DB et al. Duplex Doppler evaluation of renal allograft dysfunction. *Transplant.Proc.* 1989;21:1893-1894.
31. **Waer M**, Leenaerts P, Vanrenterghem Y et al. Factors determining the success rate of total lymphoid irradiation in clinical kidney transplantation. *Transplant.Proc.* 1989;21:1796-1797.
32. Vanrenterghem Y, **Waer M**, Roels L, Michielsen P. Optimal cyclosporin levels during the first month after cadaveric kidney transplantation. Leuven Collaborative Group for Transplantation. *Transplant.Proc.* 1989;21:1467-1468.
33. Palathumapat V, **Waer M**, van der SE, Vandeputte M. Induction of immunologic tolerance after allogeneic thymus transplantation and total lymphoid irradiation. *Transplant.Proc.* 1989;21:1108-1109.
34. Peeters A, **Waer M**, Michielsen P, Verbist L, Carton H. *Listeria monocytogenes* meningitis. *Clin.Neurol.Neurosurg.* 1989;91:29-36.
35. Palathumapat V, Vandeputte M, **Waer M**. Induction of immunological tolerance by chimeric thymus transplantation. *Thymus.* 1989;13:113-122.
36. Palathumapat V, Sobis H, Vandeputte M, Michielsen P, **Waer M**. Induction of mixed lymphocyte reaction nonresponsiveness after chimeric thymus transplantation. *Transpl.Int.* 1990;3:217-221.
37. Verresen L, **Waer M**, Vanrenterghem Y, Michielsen P. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. *Lancet.* 1990;336:1360-1362.
38. Rigauts H, Marchal G, Grieten M et al. Duplex Doppler evaluation of renal allograft dysfunction: Doppler signal quantitation and pathologic correlation. *J.Belge Radiol.* 1990;73:475-483.

39. Roels L, Vanrenterghem Y, **Waer M**, Gruwez J, Michielsen P. Effect of a presumed consent law on organ retrieval in Belgium. *Transplant.Proc.* 1990;22:2078-2079.
40. **Waer M**, Vandeputte M. Allogeneic thymus transplantation as a means to induce transplantation tolerance. *Transplant.Proc.* 1990;22:1970.
41. Vanrenterghem Y, **Waer M**, Roels L et al. Long-term prognosis of cadaver renal allografts transplanted with cyclosporine as basic immunosuppression. The Leuven Collaborative Group for Transplantation. *Transplant.Proc.* 1990;22:1691-1692.
42. De RD, **Waer M**, Vandeputte M, van der SE. Mechanisms involved in the differential recovery of CD4 and CD8 T-lymphocytes after local irradiation in mice. *Radiother.Oncol.* 1990;18:299-305.
43. **Waer M**, Palathumpat V, Sobis H, Vandeputte M. Induction of transplantation tolerance in mice across major histocompatibility barrier by using allogeneic thymus transplantation and total lymphoid irradiation. *J.Immunol.* 1990;145:499-504.
44. Leenarets PL, Vandeputte M, **Waer M**. Determination of mixed chimerism by a simple flow cytometry method. *J.Immunol.Methods.* 1990;130:163-169.
45. Palathumpat VC, Vandeputte MM, **Waer M**. Effects of thymus irradiation on the immune competence of T cells after total-lymphoid irradiation. *Transplantation.* 1990;50:95-100.
46. Leenaerts PL, De RD, Vandeputte M, **Waer M**. Measurement of alloantibody by flow cytometry. *J.Immunol.Methods.* 1990;130:73-79.
47. Roels L, Vanrenterghem Y, **Waer M** et al. The aging kidney donor: another answer to organ shortage? The Leuven Collaborative Group for Transplantation. *Transplant.Proc.* 1990;22:368-370.
48. **Waer M**. The role of anti-DNA antibodies in lupus nephritis. *Clin.Rheumatol.* 1990;9:111-114.
49. Van DB, Van Damme-Lombaerts R, **Waer M**. Biopsy device for obtaining kidney specimens. *Pediatr.Nephrol.* 1990;4:94-95.
50. Oosterlynck DJ, Cornillie FJ, **Waer M**, Vandeputte M, Koninckx PR. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. *Fertil.Steril.* 1991;56:45-51.
51. De RD, Sobis H, Vandeputte M, **Waer M**. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice. *J.Immunol.* 1991;146:4065-4070.
52. Verresen L, **Waer M**, Vanrenterghem Y, Michielsen P. Anaphylactoid reactions, haemodialysis, and ACE inhibitors. *Lancet.* 1991;337:1294.
53. Leenaerts P, Vandeputte M, **Waer M**. Induction of transplantation tolerance after allogeneic thymus transplantation: mechanisms involved. *Transplant.Proc.* 1991;23:567.
54. Roels L, Vanrenterghem Y, **Waer M** et al. Three years of experience with a 'presumed consent' legislation in Belgium: its impact on multi-organ donation in comparison with other European countries. The Leuven Collaborative Group for Transplantation. *Transplant.Proc.* 1991;23:903-904.
55. Vanrenterghem Y, **Waer M**, Christiaens R et al. Long-term results after cadaver kidney transplantation have also improved over the last two decades. The Leuven Collaborative Group for Transplantation. *Transplant.Proc.* 1991;23:1265-1266.
56. De RD, Sobis H, Vandeputte M, **Waer M**. A subpopulation of asialo GM1-positive cells plays a protective role in the occurrence of graft-versus-host disease (GVHD) in mice. *Transplant.Proc.* 1991;23:804.
57. Emonds MP, Dendievel J, Roels L et al. Cadaveric kidney transplantation in patients with lymphocytotoxic autoantibodies. *Transplant.Proc.* 1992;24:2502-2503.
58. Roels L, Vanrenterghem Y, **Waer M** et al. Single center experience with the CTS-HIT allocation system for highly immunized patients. The Leuven Collaborative Group for Transplantation. *Transplant.Proc.* 1992;24:2492-2493.
59. Leenaerts PL, Ceuppens JL, Van DJ, Michielsen P, **Waer M**. Evidence that stimulator cell-derived IL-6 and IL-1 are released in the mixed lymphocyte culture but are not requisite for responder T cell proliferation. *Transplantation.* 1992;54:1071-1078.
60. Mathieu C, Laureys J, Sobis H et al. 1,25-Dihydroxyvitamin D3 prevents insulinitis in NOD mice. *Diabetes.* 1992;41:1491-1495.
61. Oosterlynck DJ, Meuleman C, **Waer M**, Vandeputte M, Koninckx PR. The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis. *Fertil.Steril.* 1992;58:290-295.
62. **Waer M**, Strober S. The goal of specific immunologic unresponsiveness in clinical kidney transplantation. *Semin.Nephrol.* 1992;12:325-331.
63. Vanrenterghem Y, **Waer M**, Christiaens MR, Michielsen P. Bilateral nephrectomy of the native kidneys reduces the incidence of arterial hypertension and erythrocytosis in kidney graft recipients treated with cyclosporin. *Leuven Collaborative Group for Transplantation. Transpl.Int.* 1992;5 Suppl 1:S35-7.:S35-S37.
64. Kuschnaroff LM, De BK, Vandeputte M, **Waer M**. Factors involved in peripheral T cell tolerance: the extent of clonal deletion or clonal anergy depends on the age of the tolerized lymphocytes. *Transpl.Int.* 1992;5 Suppl 1:S589-93.:S589-S593.

65. De RD, Landuyt W, **Waer M**, Vandeputte M, van der SE. The influence of neonatal thymectomy on the development of radiation myelopathy in rats. *Int.J.Radiat.Oncol.Biol.Phys.* 1992;24:133-137.
66. De RD, **Waer M**, Vandeputte M et al. Changes of lymphocyte subsets after local irradiation for early stage breast cancer and seminoma testis: long-term increase of activated (HLA-DR+) T cells and decrease of "naive" (CD4-CD45R) T lymphocytes. *Eur.J.Cancer.* 1992;28A:1729-1734.
67. Lammens M, Robberecht W, **Waer M**, Carton H, Dom R. Purulent meningitis due to aspergillosis in a patient with systemic lupus erythematosus. *Clin.Neurol.Neurosurg.* 1992;94:39-43.
68. **Waer M**, Salam A, Vandeputte M. Protective role of asialo GM1+, NK1.1- cells in the occurrence of graft-versus-host disease after total lymphoid irradiation. *Transplantation.* 1993;56:1049-1051.
69. Oosterlynck DJ, Meuleman C, **Waer M**, Koninckx PR, Vandeputte M. Immunosuppressive activity of peritoneal fluid in women with endometriosis. *Obstet.Gynecol.* 1993;82:206-212.
70. **Waer M**, Salam A, Vandeputte M. Impaired B-cell tolerance in complete as compared with mixed chimeras after allogeneic bone marrow transplantation. *Transplant.Proc.* 1993;25:1281-1282.
71. Mathieu C, Vandeputte M, Bouillon R, **Waer M**. Protection against autoimmune diabetes by induction of mixed bone marrow chimerism. *Transplant.Proc.* 1993;25:1266-1267.
72. Kuschnaroff LM, Heremans H, Dillen C et al. Role of interferon-gamma in the induction of clonal deletion after injection of staphylococcal enterotoxin B. *Transplant.Proc.* 1993;25:317-318.
73. Kuttler B, Mathieu C, **Waer M**, Hahn HJ, Bouillon R. Lack of disease recurrence in diabetic BB/Pfd rats after syngeneic islet transplantation. *Autoimmunity.* 1993;15:107-112.
74. Oosterlynck DJ, Cornillie FJ, **Waer M**, Koninckx PR. Immunohistochemical characterization of leucocyte subpopulations in endometriotic lesions. *Arch.Gynecol.Obstet.* 1993;253:197-206.
75. Lin Y, Sobis H, Vandeputte M, **Waer M**. Long-term xenograft survival and suppression of xenoantibody formation in the hamster-to-rat heart transplant model using a combination therapy of leflunomide and cyclosporine. *Transplant.Proc.* 1994;26:3202.
76. Mathieu C, Laureys J, **Waer M**, Bouillon R. Prevention of autoimmune destruction of transplanted islets in spontaneously diabetic NOD mice by KH1060, a 20-epi analog of vitamin D: synergy with cyclosporine. *Transplant.Proc.* 1994;26:3128-3129.
77. Mathieu C, Bouillon R, Rutgeerts O, Vandeputte M, **Waer M**. Potential role of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> as a dose-reducing agent for cyclosporine and FK 506. *Transplant.Proc.* 1994;26:3130.
78. Lin Y, Sobis H, Vandeputte M, **Waer M**. Induction therapy of leflunomide and cyclosporine allows for long-term xenograft survival under cyclosporine alone. *Transplant.Proc.* 1994;26:3052.
79. Mathieu C, **Waer M**, Laureys J, Rutgeerts O, Bouillon R. Activated form of vitamin D [1,25(OH)<sub>2</sub>D<sub>3</sub>] and its analogs are dose-reducing agents for cyclosporine in vitro and in vivo. *Transplant.Proc.* 1994;26:3048-3049.
80. Mathieu C, Kuttler B, **Waer M**, Bouillon R, Hahn HJ. Spontaneous reestablishment of self-tolerance in BB/Pfd rats. *Transplantation.* 1994;58:349-354.
81. Mathieu C, **Waer M**, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D<sub>3</sub>. *Diabetologia.* 1994;37:552-558.
82. Mathieu C, **Waer M**, Kuttler B, Hahn HJ, Bouillon R. Diabetic BB/PFD rats reject MHC incompatible islet grafts, but do not destroy MHC compatible islet grafts. *Transplant.Proc.* 1994;26:718-719.
83. Oosterlynck DJ, Meuleman C, **Waer M**, Koninckx PR. CO<sub>2</sub>-laser excision of endometriosis does not improve the decreased natural killer activity. *Acta Obstet.Gynecol.Scand.* 1994;73:333-337.
84. Oosterlynck DJ, Meuleman C, **Waer M**, Koninckx PR. Transforming growth factor-beta activity is increased in peritoneal fluid from women with endometriosis. *Obstet.Gynecol.* 1994;83:287-292.
85. Salam A, Vandeputte M, **Waer M**. Clonal deletion and clonal anergy in allogeneic bone marrow chimeras prepared with TBI or TLI. *Transpl.Int.* 1994;7 Suppl 1:S457-61.:S457-S461.
86. Roels L, **Waer M**, Coosemans W, Christiaens MR, Vanrenterghem Y. The influence of donor age on initial and long-term renal allograft outcome. *Leuven Collaborative Group for Transplantation. Transpl.Int.* 1994;7 Suppl 1:S303-5.:S303-S305.
87. Vanrenterghem Y, **Waer M**, Roels L et al. A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. *Leuven Collaborative Group for Transplantation. Transpl.Int.* 1994;7 Suppl 1:S243-6.:S243-S246.
88. Oosterlynck DJ, Meuleman C, Lacquet FA, **Waer M**, Koninckx PR. Flow cytometry analysis of lymphocyte subpopulations in peritoneal fluid of women with endometriosis. *Am.J.Reprod.Immunol.* 1994;31:25-31.
89. Oosterlynck DJ, Lacquet FA, **Waer M**, Koninckx PR. Lymphokine-activated killer activity in women with endometriosis. *Gynecol.Obstet.Invest.* 1994;37:185-190.
90. Lin Y, Vandeputte M, **Waer M**. Effect of leflunomide and cyclosporine on the occurrence of chronic xenograft lesions. *Kidney Int.Suppl.* 1995;52:S23-8.:S23-S28.
91. Branisteanu DD, **Waer M**, Sobis H et al. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)<sub>2</sub>D<sub>3</sub>. *J.Neuroimmunol.* 1995;61:151-160.

92. Casteels K, Bouillon R, **Waer M**, Mathieu C. Immunomodulatory effects of 1,25-dihydroxyvitamin D<sub>3</sub>. *Curr.Opin.Nephrol.Hypertens.* 1995;4:313-318.
93. Verstuyf A, Mathieu C, Verlinden L et al. Differentiation induction of human leukemia cells (HL60) by a combination of 1,25-dihydroxyvitamin D<sub>3</sub> and retinoic acid (all trans or 9-cis). *J.Steroid Biochem.Mol.Biol.* 1995;53:431-441.
94. Mathieu C, **Waer M**, Casteels K, Laureys J, Bouillon R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D<sub>3</sub>, KH1060. *Endocrinology.* 1995;136:866-872.
95. Roels L, Coosemans W, Christiaens MR, **Waer M**, Vanrenterghem Y. The relative impact of legislative incentives on multi-organ donation rates in Europe. *Transplant.Proc.* 1995;27:795-796.
96. Mathieu C, Bouillon R, Rutgeerts O, **Waer M**. Induction of mixed bone marrow chimerism as potential therapy for autoimmune (type I) diabetes: experience in the NOD model. *Transplant.Proc.* 1995;27:640-641.
97. Lin Y, Sobis H, Vandeputte M, **Waer M**. Mechanism of leflunomide-induced prevention of xenoantibody formation and xenograft rejection in the hamster to rat heart transplantation model. *Transplant.Proc.* 1995;27:305-306.
98. Lin Y, Sobis H, Vandeputte M, **Waer M**. Natural killer cells, antibody-dependent cellular cytotoxicity, and complement synthesis by the xenograft itself play a role in xenograft rejection. *Transplant.Proc.* 1995;27:286-287.
99. Peeters J, Christiaens MR, Coosemans W et al. A single-center multiple regression analysis of covariates associated with long-term cadaveric renal allograft survival: further improvement of long-term results with CsA. *Clin.Transpl.* 1995;255-260.
100. Bouillon R, Verstuyf A, Branisteanu D, **Waer M**, Mathieu C. [Immune modulation by vitamin D analogs in the prevention of autoimmune diseases]. *Verh.K.Acad.Geneeskd.Belg.* 1995;57:371-385.
101. Lin Y, **Waer M**. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycin or leflunomide. *Transplant.Proc.* 1996;28:3159.
102. Lin Y, Segers C, Mikhalsky D, Schonharting M, **Waer M**. Xanthines: ideal immunosuppressants for combination with cyclosporine? *Transplant.Proc.* 1996;28:3102.
103. Casteels K, **Waer M**, Bouillon R et al. Prevention of type I diabetes by late intervention with nonhypercalcemic analogues of vitamin D<sub>3</sub> in combination with cyclosporin A. *Transplant.Proc.* 1996;28:3095.
104. Lin Y, **Waer M**. In vivo mechanism of action of leflunomide: selective inhibition of the capacity of B lymphocytes to make T-independent xenoantibodies. *Transplant.Proc.* 1996;28:3085.
105. Lin Y, Rutgeerts O, **Waer M**. Route of administration determines the efficacy of rapamycin but not the mechanisms of tolerance induced by it in rats. *Transplant.Proc.* 1996;28:3057.
106. Lin Y, Segers C, **Waer M**. Efficacy of the malononitrilamide X 920715 as compared with leflunomide in cardiac allo- and xenotransplantation in rats. *Transplant.Proc.* 1996;28:3036.
107. **Waer M**. The use of leflunomide in transplantation immunology. *Transpl.Immunol.* 1996;4:181-185.
108. Lin Y, Goebels J, Vandeputte M, **Waer M**. Immunosuppressants suppressing signal 2 of T-cell activation enable CsA to induce operational transplantation tolerance in a strongly immunogenic heart allograft model in rats. *Transplant.Proc.* 1996;28:977-978.
109. Lin Y, Vandeputte M, **Waer M**. Effect of leflunomide on T-independent xenoantibody formation in rats receiving hamster heart xenografts. *Transplant.Proc.* 1996;28:952.
110. Lin Y, Vandeputte M, **Waer M**. Difference in tolerization of T-independent and T-dependent xenoantibody formation after cardiac xenotransplantation in rats. *Transplant.Proc.* 1996;28:741.
111. Lin Y, Vandeputte M, **Waer M**. Mechanisms involved in long-term hamster-to-rat cardiac xenograft survival. *Transplant.Proc.* 1996;28:683.
112. Salam A, **Waer M**. Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation. *Transplantation.* 1996;61:826-830.
113. Lin Y, Vandeputte M, **Waer M**. A short-term combination therapy with cyclosporine and rapamycin or leflunomide induces long-term heart allograft survival in a strongly immunogenic strain combination in rats. *Transpl.Int.* 1996;9 Suppl 1:S328-30.:S328-S330.
114. Stas KJ, Louwagie PG, Van Damme BJ et al. Isolated zygomycosis in a bought living unrelated kidney transplant. *Transpl.Int.* 1996;9:600-602.
115. Emonds MP, Mytilineos Y, Scherer S et al. A single center evaluation of the Collaborative Transplant Study (CTS) DNA project. *Transpl.Int.* 1996;9:468-475.
116. Sobis H, **Waer M**, Vandeputte M. Normal and malignant trophoblasts do not recruit granulated metrial gland cells. *Tumour.Biol.* 1996;17:13-19.
117. Lin Y, **Waer M**. Xenotransplantation: a clinically achievable goal? *Acta Gastroenterol.Belg.* 1997;60:287-291.

118. Lin Y, Vandeputte M, **Waer M**. Contribution of activated macrophages to the process of delayed xenograft rejection. *Transplantation*. 1997;64:1677-1683.
119. Kuschnaroff LM, Goebels J, Valckx D et al. Increased mortality and impaired clonal deletion after staphylococcal enterotoxin B injection in old mice: relation to cytokines and nitric oxide production. *Scand.J.Immunol*. 1997;46:469-478.
120. Kuschnaroff LM, Valckx D, Goebels J et al. Effect of treatments with cyclosporin A and anti-interferon-gamma antibodies on the mechanisms of immune tolerance in staphylococcal enterotoxin B primed mice. *Scand.J.Immunol*. 1997;46:459-468.
121. Lin Y, Goebels J, Vandeputte M, **Waer M**. Long-term survival of hamster-to-rat heart xenografts based on mechanisms of accommodation and tolerance of CD5 B cells. *Transplant.Proc*. 1997;29:2355.
122. Lin Y, Goebels J, Vandeputte M, **Waer M**. Rejection of cardiac xenografts by NK cells and macrophages. *Transplant.Proc*. 1997;29:2354.
123. Sefrioui H, Moodley J, Rutgeerts O et al. Stable mixed chimerism induced by total lymphoid irradiation or by total body irradiation is maintained by different mechanisms and leads to different graft versus leukemia or graft rejection reactions. *Transplant.Proc*. 1997;29:2352.
124. Lin Y, Goebels J, Rutgeerts O et al. Use of the methylxanthine derivative A802715 in transplantation immunology: I. Strong in vitro inhibitory effects on CD28-costimulated T cell activities. *Transplantation*. 1997;63:1813-1818.
125. Lin Y, Segers C, Mikhalsky D et al. Use of the methylxanthine derivative A802715 in transplantation immunology: II. In vivo experiments. *Transplantation*. 1997;63:1734-1738.
126. Lin Y, Vandeputte M, **Waer M**. Factors involved in rejection of concordant xenografts in complement-deficient rats. *Transplantation*. 1997;63:1705-1712.
127. Lin Y, Vandeputte M, **Waer M**. Natural killer cell- and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses. *J.Immunol*. 1997;158:5658-5667.
128. Vanwalleghem J, Coosemans W, Raat H, **Waer M**, Vanrenterghem Y. Peritransplant lymphocele causing arterial hypertension by a Page kidney phenomenon. Leuven Collaborative Group for Transplantation. *Nephrol.Dial.Transplant*. 1997;12:823-824.
129. Salam A, Moodley J, **Waer M**. Presence of intrinsic B lymphocyte tolerance in mixed but not in complete semiallogeneic bone marrow chimeras. *Transplantation*. 1997;63:699-704.
130. Lin Y, Vandeputte M, **Waer M**. Leflunomide-mediated tolerance of B lymphocytes for T-independent xenoantigens needs the presence of these xenoantigens. *Transplant.Proc*. 1997;29:1304.
131. Lin Y, Schonharting M, Goebels J et al. Use of methylxanthines (MeXa) as immunosuppressive drugs for organ transplantation. *Transplant.Proc*. 1997;29:1279.
132. Kuschnaroff L, Valckx D, Froyen G et al. Opposing effects of cyclosporin A and anti-interferon-gamma antibodies on immune tolerance mechanisms. *Transplant.Proc*. 1997;29:1156-1157.
133. Mathieu C, Casteels K, Bouillon R, **Waer M**. Protection against autoimmune diabetes in mixed bone marrow chimeras: mechanisms involved. *J.Immunol*. 1997;158:1453-1457.
134. Waer M. New immunosuppressive agents for organ transplantation. *Acta Clin.Belg*. 1997;52:199-203.
135. Casteels K, **Waer M**, Bouillon R et al. 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. *Clin.Exp.Immunol*. 1998;112:181-187.
136. Casteels KM, Gysemans CA, **Waer M** et al. Sex difference in resistance to dexamethasone-induced apoptosis in NOD mice: treatment with 1,25(OH)2D3 restores defect. *Diabetes*. 1998;47:1033-1037.
137. Casteels K, **Waer M**, Laureys J et al. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. *Transplantation*. 1998;65:1225-1232.
138. Hatse S, Naesens L, Degreve B et al. In vitro and in vivo inhibitory activity of the differentiation-inducing agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against rat choriocarcinoma. *Adv.Exp.Med.Biol*. 1998;431:605-9.:605-609.
139. Hatse S, Naesens L, Degreve B et al. Potent antitumor activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine in choriocarcinoma-bearing rats. *Int.J.Cancer*. 1998;76:595-600.
140. Lin Y, Vandeputte M, **Waer M**. Accommodation and T-independent B cell tolerance in rats with long term surviving hamster heart xenografts. *J.Immunol*. 1998;160:369-375.
141. Mathieu C, Casteels K, **Waer M** et al. Prevention of diabetes recurrence after syngeneic islet transplantation in NOD mice by analogues of 1,25(OH)2D3 in combination with cyclosporin A: mechanism of action involves an immune shift from Th1 to Th2. *Transplant.Proc*. 1998;30:541.
142. Coosemans W, Peeters J, Aerts R et al. Complications and outcome of combined kidney-pancreas transplantation for end-stage diabetic nephropathy: a retrospective single-center analysis. Leuven Collaborative Group for Transplantation. *Transplant.Proc*. 1998;30:274-275.

143. Lin Y, Ji P, Xia G, Vandeputte M, **Waer M**. Blockade of induced xenoantigen expression prevents rejection after retransplantation of accommodated hamster-to-rat heart xenografts. *Transplantation*. 1998;65:340-345.
144. Lin Y, Vandeputte M, **Waer M**. Suppression of T-independent IgM xenoantibody formation by leflunomide during xenografting of hamster hearts in rats. *Transplantation*. 1998;65:332-339.
145. Lin Y, Goebels J, Xia G et al. Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment. *Nat.Med.* 1998;4:173-180.
146. Casteels KM, Mathieu C, **Waer M** et al. Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. *Endocrinology*. 1998;139:95-102.
147. Sefrioui H, Billiau AD, Overbergh L, Rutgeerts O, **Waer M**. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells. *Transplantation*. 1999;68:1560-1567.
148. Naesens L, Hatse S, Segers C et al. 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats. *Oncol.Res.* 1999;11:195-203.
149. Xia G, Ji P, Rutgeerts O, **Waer M**. Maintenance and reversibility of natural killer cell- and T cell-independent B lymphocyte xenotolerance in athymic nude rats. *Transplantation*. 1999;68:1181-1188.
150. Kuschnaroff LM, Overbergh L, Sefrioui H et al. Effect of staphylococcal enterotoxin B injection on the development of experimental autoimmune encephalomyelitis: influence of cytokine and inducible nitric oxide synthase production. *J.Neuroimmunol.* 1999;99:157-168.
151. Ji P, Xia G, Sefrioui H et al. Induction of T-independent xenotolerance in a semi-discordant hamster-to-presensitized, nude rat model. *Transplantation*. 1999;68:130-136.
152. Overbergh L, Valckx D, **Waer M**, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. *Cytokine*. 1999;11:305-312.
153. Xia GL, Ji P, Rutgeerts O, Goebels J, **Waer M**. Characteristics of B lymphocyte and natural killer cell xenotolerance in a concordant hamster-to-athymic rat cardiac xenotransplantation model. *Transplant.Proc.* 1999;31:926-927.
154. Sefrioui H, Billiau AD, Overbergh L, Rutgeerts O, **Waer M**. Tolerance in MIsa mismatched chimeras prepared with allogeneic bone marrow alone or in combination with syngeneic bone marrow. *Transplant.Proc.* 1999;31:702-703.
155. Maes B, Vanwalleghem J, Kuypers D et al. IgA antiglomerular basement membrane disease associated with bronchial carcinoma and monoclonal gammopathy. *Am.J.Kidney Dis.* 1999;33:E3.
156. Gysemans CA, Waer M, Valckx D et al. Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. *Diabetes*. 2000;49:1992-1997.
157. Koshiba T, Ji P, Tanaka K et al. Tolerance induction with FTY720 and donor-specific blood transfusion: discrepancy between heart transplantation and intestinal transplantation. *Transplant.Proc.* 2000;32:1255-1257.
158. Gysemans C, **Waer M**, Laureys J et al. Islet xenograft destruction in the hu-PBL-severe combined immunodeficient (SCID) mouse necessitates anti-CD3 preactivation of human immune cells. *Clin.Exp.Immunol.* 2000;121:557-565.
159. Xia GL, Ji P, Vandeputte M, **Waer M**. Synergistic effect of pretransplant xenogeneic blood transfusion with NK cell and/or B-cell immunosuppression to modulate T-cell-independent xenoreactivity. *Transplant.Proc.* 2000;32:1038.
160. Xia GL, Vandeputte M, **Waer M**. Induction of combined T-cell-dependent and T-cell-independent xenograft tolerance by thymus/heart composite grafts. *Transplant.Proc.* 2000;32:1031.
161. Ji P, Xia GL, **Waer M**. Complement- and xenoantibody-independent discordant xenograft rejection in a guinea pig to rat model. *Transplant.Proc.* 2000;32:935.
162. Ji P, Xia GL, **Waer M**. Absence of cross-reactivity between xenoantibodies directed against concordant or discordant xenoantigens in rats. *Transplant.Proc.* 2000;32:861.
163. Sefrioui H, Billiau AD, **Waer M**. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells. *Transplantation*. 2000;70:348-353.
164. Xia G, Ji P, Rutgeerts O, **Waer M**. Natural killer cell- and macrophage mediated discordant guinea pig-->rat xenograft rejection in the absence of complement, xenoantibody and T cell immunity. *Transplantation*. 2000;70:86-93.
165. Overbergh L, Decallonne B, **Waer M** et al. 1alpha,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). *Diabetes*. 2000;49:1301-1307.

166. **Waer M.** Mixed bone marrow chimerism across discordant xenogeneic barriers: the solution for inducing xenotransplant tolerance? *Transplantation*. 2000;69:2482-2483.
167. Xia G, Ji P, Rutgeerts O, Vandeputte M, **Waer M.** Immunomodulatory effects of pretransplant donor blood transfusion on T-cell-independent xenoreactive immunity. *Transplantation*. 2000;69:1695-1704.
168. van EE, Branisteanu DD, Verstuyf A et al. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. *Transplantation*. 2000;69:1932-1942.
169. **Waer M,** Ji P, Xia GL. Induction of xenotransplant tolerance. *Verh.K.Acad.Geneeskd.Belg.* 2000;62:137-151.
170. Emonds MP, Herman J, Dendievel J, **Waer M,** Van Damme-Lombaerts R. Evaluation of anti-human leukocyte antigen allo-immunization in pediatric cadaveric kidney transplantation. *Pediatr.Transplant.* 2000;4:6-11.
171. Xia GL, Ji P, Rutgeerts O, **Waer M.** Approaches toward T cell-independent and -dependent xenograft tolerance. *Transplant.Proc.* 2000;32:371-373.
172. Moons P, De GS, Versteven K et al. Psychometric properties of the "Modified Transplant Symptom Occurrence and Symptom Distress Scale". *J.Nurs.Meas.* 2001;9:115-134.
173. **Waer M.** Induction of xenotransplantation tolerance: a privileged role for the malononitrilamides. *Transplant.Proc.* 2001;33:2429-2430.
174. Gysemans C, **Waer M,** Laureys J, Bouillon R, Mathieu C. A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. *Transplant.Proc.* 2001;33:2365.
175. Gysemans C, **Waer M,** Laureys J, Bouillon R, Mathieu C. Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in nonobese diabetic mice. *Transplant.Proc.* 2001;33:2094-2095.
176. Koshiba T, Van DB, Ji P et al. Intestinal allografts delay rejection and prolong survival of combined donor-specific and third party solid organ transplants. *Transplant.Proc.* 2001;33:1550-1552.
177. Koshiba T, Ji P, Lu Y, **Waer M,** Pirenne J. The technical aspects of combined intestinal and heart transplantation in rats. *Transplant.Proc.* 2001;33:532-534.
178. Koshiba T, Van DB, Ji P et al. Addition of steroids blocks the tolerogenic potential of donor-specific blood transfusion. *Transplant.Proc.* 2001;33:375-376.
179. Billiau AD, Sefrioui H, Overbergh L et al. The graft-versus-leukemia effect in allogeneic irradiation bone marrow chimeras: possible suppressive role of irradiation-induced TGF-beta. *Transplant.Proc.* 2001;33:336-337.
180. Billiau AD, Sefrioui H, Overbergh L et al. Transforming growth factor-beta inhibits lymphokine activated killer cytotoxicity of bone marrow cells: implications for the graft-versus-leukemia effect in irradiation allogeneic bone marrow chimeras. *Transplantation.* 2001;71:292-299.
181. Xia G, Goebels J, Rutgeerts O, Vandeputte M, **Waer M.** Transplantation tolerance and autoimmunity after xenogeneic thymus transplantation. *J.Immunol.* 2001;166:1843-1854.
182. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, **Waer M.** Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. *Blood.* 2002;100:1894-1902.
183. Koshiba T, Van DB, Kitade H et al. Induction of tolerance by donor-specific blood transfusion in a model of intestinal transplantation: technical and immunological aspects. *Transplant.Proc.* 2002;34:1033-1039.
184. Koshiba T, Van DB, Lu Y et al. Combined use of FTY720 and cyclosporine A prevents chronic allograft vasculopathy. *Transplant.Proc.* 2002;34:748-749.
185. Gysemans C, van EE, Overbergh L et al. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3. *Clin.Exp.Immunol.* 2002;128:213-220.
186. Pirenne J, Koshiba T, Geboes K et al. Complete freedom from rejection after intestinal transplantation using a new tolerogenic protocol combined with low immunosuppression. *Transplantation.* 2002;73:966-968.
187. Koshiba T, Kitade H, **Waer M** et al. Break of tolerance via donor-specific blood transfusion by high doses of steroids: a differential effect after intestinal transplantation and heart transplantation. *Transplant.Proc.* 2003;35:3153-3155.
188. Koshiba T, Kitade H, Van DB et al. Regulatory cell-mediated tolerance does not protect against chronic rejection. *Transplantation.* 2003;76:588-596.
189. Gysemans C, Stoffels K, Giulietti A et al. Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents. *Diabetologia.* 2003;46:1115-1123.
190. Koshiba T, Van DB, Ji P et al. The effect of FTY 720 on engraftment in a model of spontaneous allograft acceptance. *Transpl.Int.* 2003;16:383-390.
191. Yan Y, Devos T, Yu L et al. Pathogenesis of autoimmunity after xenogeneic thymus transplantation. *J.Immunol.* 2003;170:5936-5946.

192. Koshiba T, Van DB, Rutgeerts O, **Waer M**, Pirenne J. FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A. *Transplantation*. 2003;75:945-952.
193. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, **Waer M**. Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. *Blood*. 2003;102:740-748.
194. Koshiba T, Giulietti A, Van DB et al. Paradoxical early upregulation of intragraft Th1 cytokines is associated with graft acceptance following donor-specific blood transfusion. *Transpl.Int.* 2003;16:179-185.
195. Yau Y, **Waer M**. Opportunities and risks of xenogeneic thymus transplantation. *Transplantation*. 2003;75:263-264.
196. Kitade H, Kawai M, Koshiba T et al. Early accumulation of interferon-gamma in grafts tolerized by donor-specific blood transfusion: friend or enemy? *Transplantation*. 2004;78:1747-1755.
197. Devos T, **Waer M**, Billiau AD. Cross-species chemoattraction and xenograft failure: do neutrophils play a role? *Transplantation*. 2004;78:1717-1718.
198. Kitade H, Kawai M, Rutgeerts O et al. Early presence of regulatory cells in transplanted rats rendered tolerant by donor-specific blood transfusion. *J.Immunol.* 2005;175:4963-4970.
199. Boudewijns M, Jeurissen A, Wuyts M et al. Blockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides. *J.Leukoc.Biol.* 2005;78:1060-1069.
200. Kawai M, Kitade H, Mathieu C, **Waer M**, Pirenne J. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. *Transplantation*. 2005;79:1073-1077.
201. Devos T, Yan Y, Segers C et al. Role of CD4+ and CD8+ T cells in the rejection of heart or islet xenografts in recipients with xenotolerance in the innate immune compartment. *Transplant.Proc.* 2005;37:516-517.
202. Yu L, Yan Y, Li S et al. Induction and maintenance of T-dependent or T-independent xenotolerance by nonprimarily-vascularized skin or thymus grafts. *Transplantation*. 2005;79:520-527.
203. Pirenne J, Kitade H, Kawai M et al. Regulatory cells, TH1/TH2 unbalance, and antibody-induced chronic rejection in operational tolerance induced by donor-specific blood transfusion. *Transplantation*. 2005;79:S25-S27.
204. Yan Y, Verbeken E, Yu L et al. Effects of a short course of leflunomide on T-independent B-lymphocyte xenoreactivity and on susceptibility of xenografts to acute or chronic rejection. *Transplantation*. 2005;79:135-141.
205. Overbergh L, Stoffels K, **Waer M** et al. Immune regulation of 25-hydroxyvitamin D-1alpha-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-gamma-mediated induction. *J.Clin.Endocrinol.Metab.* 2006;91:3566-3574.
206. Sprangers B, **Waer M**, Billiau AD. Xenograft rejection--all that glitters is not Gal. *Nephrol.Dial.Transplant.* 2006;21:1486-1488.
207. Jeurissen A, Billiau AD, Moens L et al. CD4+ T lymphocytes expressing CD40 ligand help the IgM antibody response to soluble pneumococcal polysaccharides via an intermediate cell type. *J.Immunol.* 2006;176:529-536.
208. Li S, Yan Y, Lin Y et al. Rapidly induced, T-cell independent xenoantibody production is mediated by marginal zone B cells and requires help from NK cells. *Blood*. 2007;110:3926-3935.
209. Sprangers B, Van WB, Fevery S, **Waer M**, Billiau AD. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. *Nat.Clin.Pract.Oncol.* 2007;4:404-414.
210. Van WB, Sprangers B, Rutgeerts O et al. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect. *Biol.Blood Marrow Transplant.* 2007;13:627-637.
211. Fevery S, Billiau AD, Sprangers B et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. *Leukemia*. 2007;21:1451-1459.
212. Sprangers B, Fevery S, Van WB et al. Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease? *Front Biosci.* 2007;12:4568-94.:4568-4594.
213. Li S, **Waer M**, Billiau AD. Xenotransplantation: Role of natural immunity. *Transpl.Immunol.* 2008
214. Van WB, Sprangers B, Dubois B, **Waer M**, Billiau AD. Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: perspective on mechanisms of action. *J.Neuroimmunol.* 2008;197:89-98.
215. Devos T, Shengqiao L, Gysemans C et al. Late CD8+ T cell-dependent xenoantibody production in innate tolerant nude rats after hamster islet grafting but not after hamster heart grafting. *Transplantation*. 2008;85:1489-1495.
216. Van d, V, Ostrowski T, Sproat B et al. Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants. *J.Med.Chem.* 2008;51:3020-3029.
217. Sprangers B, , Billiau AD. Xenotransplantation: where are we in 2008? *Kidney Int.* 2008;74:14-21.

218. Pirenne J, Kawai M, Kitade H et al. Intestinal transplantation: from the laboratory to the clinics. *Acta Chir Belg.* 2008;108:52-57.
219. Devos T, Sprangers B, Lin Y et al. Occurrence of autoimmunity after xenothymus transplantation in T-cell-deficient mice depends on the thymus transplant technique. *Transplantation.* 2008;85:640-644.
220. Tjwa M, Bellido-Martin L, Lin Y et al. Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. *Blood.* 2008;111:4096-4105.
221. Gysemans C, van EE, Overbergh L et al. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. *Diabetes.* 2008;57:269-275.
222. Sprangers B, Van WB, Luyckx A et al. Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect. *Leukemia.* 2009;23:340-349.